A New Jersey woman has been given a second chance at life, thanks to a groundbreaking cancer therapy. Pamela Goldberger, 65, received a devastating diagnosis of glioblastoma in 2023, with an average survival rate of just 14 to 16 months even with surgery.
Goldberger’s initial symptoms were subtle, with a severe bout of nausea being the most prominent. However, her diagnosis was confirmed after experiencing confusion during a dinner, using her fork as a knife and vice versa.
Following neurological testing, including MRIs and a CAT scan, Goldberger was diagnosed with a brain tumor. She described the news as devastating, especially because she feared she would not see her grandchildren grow up.
After being admitted to the hospital, Goldberger was scheduled for brain surgery. However, the head of neurosurgery offered her the opportunity to participate in a clinical trial for an individualized stem cell therapy for glioblastoma. She underwent six weeks of chemotherapy and radiation, followed by six weeks of the cell therapy and a year of chemo maintenance.
Despite a slow healing process, Goldberger eventually began to feel like herself again once the oral chemotherapy ended. Now, 2-½ years after her diagnosis, she is alive, healthy, and able to play tennis multiple times a week.
The clinical trial, led by Dr. Joseph Georges, aimed to create a vaccine from the patient’s tumor to help the immune system detect and kill cancer cells. Positive results were observed in the 16 participants, with improved survival rates and minimal side effects.
Goldberger, who continues to have regular check-ins with her doctors, is enjoying her life to the fullest. She recommends other glioblastoma patients to consider clinical trials and prioritize their healing journey. By following medical advice, staying active, eating well, and surrounding oneself with positivity, Goldberger believes that a combination of these factors, along with excellent medical care and the clinical trial, contributed to her survival.
Patients with recurrent glioblastoma are encouraged to explore clinical trials as a potential treatment option, according to healthcare experts.
Diakonos Oncology recently initiated a phase 2 clinical trial for DOC1021, with the first patient being dosed on July 22. The trial will be conducted at 20 different sites across the United States, providing opportunities for eligible patients to participate.
